DK1937673T3 - Imidazolderivater som hæmmere af tafi-a - Google Patents
Imidazolderivater som hæmmere af tafi-a Download PDFInfo
- Publication number
- DK1937673T3 DK1937673T3 DK06792327.6T DK06792327T DK1937673T3 DK 1937673 T3 DK1937673 T3 DK 1937673T3 DK 06792327 T DK06792327 T DK 06792327T DK 1937673 T3 DK1937673 T3 DK 1937673T3
- Authority
- DK
- Denmark
- Prior art keywords
- ylmethyl
- imidazol
- propionic acid
- amino
- pyridin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 135
- 238000000034 method Methods 0.000 claims description 108
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 80
- -1 tetrahydronaphthalenyl Chemical group 0.000 claims description 51
- 239000002253 acid Substances 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 16
- 208000007536 Thrombosis Diseases 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 6
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims description 6
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 claims description 6
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- 102000009123 Fibrin Human genes 0.000 claims description 6
- 108010073385 Fibrin Proteins 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 229950003499 fibrin Drugs 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims description 5
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 claims description 5
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 5
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims description 5
- 208000005189 Embolism Diseases 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 230000005526 G1 to G0 transition Effects 0.000 claims description 5
- 230000003176 fibrotic effect Effects 0.000 claims description 5
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 claims description 5
- 229940125670 thienopyridine Drugs 0.000 claims description 5
- 239000002175 thienopyridine Substances 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- ICRUBEPJCVPMNL-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[(5-phenyl-1,2-oxazol-3-yl)methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C=2C=CC=CC=2)=C1 ICRUBEPJCVPMNL-UHFFFAOYSA-N 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 230000002439 hemostatic effect Effects 0.000 claims description 4
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 4
- WUFULKRXLAAIOW-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[(5-cyclobutyl-1,2-oxazol-3-yl)methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C2CCC2)=C1 WUFULKRXLAAIOW-UHFFFAOYSA-N 0.000 claims description 3
- JUCDKZGTEYNOQG-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[(5-cyclobutyl-1,3,4-thiadiazol-2-yl)methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NN=C(C2CCC2)S1 JUCDKZGTEYNOQG-UHFFFAOYSA-N 0.000 claims description 3
- ROGQHVIEDHZKCC-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C2CC2)=C1 ROGQHVIEDHZKCC-UHFFFAOYSA-N 0.000 claims description 3
- WJYLALUIJRBXNY-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[(5-phenyl-1,2,4-oxadiazol-3-yl)methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C=2C=CC=CC=2)=N1 WJYLALUIJRBXNY-UHFFFAOYSA-N 0.000 claims description 3
- JZHRFXBDACOBLH-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[(5-phenyl-1,3,4-thiadiazol-2-yl)methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NN=C(C=2C=CC=CC=2)S1 JZHRFXBDACOBLH-UHFFFAOYSA-N 0.000 claims description 3
- DYKKMTWSDXRXGT-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[2-[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]ethyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CCC1=NOC(C=2SC(Cl)=CC=2)=C1 DYKKMTWSDXRXGT-UHFFFAOYSA-N 0.000 claims description 3
- AKUMJFBHNQSTIM-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[3-[4-[(4-chlorophenyl)methoxy]phenyl]-1,2,4-oxadiazol-5-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NC(C=2C=CC(OCC=3C=CC(Cl)=CC=3)=CC=2)=NO1 AKUMJFBHNQSTIM-UHFFFAOYSA-N 0.000 claims description 3
- ICBMGIUWMBBJRF-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=CC(C=2C=CC=CC=2)=C(C(F)(F)F)S1 ICBMGIUWMBBJRF-UHFFFAOYSA-N 0.000 claims description 3
- WPFJLHZJMTWIBH-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(2,3-dihydro-1,4-benzodioxin-6-yl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C=2C=C3OCCOC3=CC=2)=C1 WPFJLHZJMTWIBH-UHFFFAOYSA-N 0.000 claims description 3
- UVBCJMPJTVONRR-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(2,3-dihydro-1h-inden-5-yl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C=2C=C3CCCC3=CC=2)=C1 UVBCJMPJTVONRR-UHFFFAOYSA-N 0.000 claims description 3
- BUFFRJSTCDQUNK-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(4-benzylphenyl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C=2C=CC(CC=3C=CC=CC=3)=CC=2)=C1 BUFFRJSTCDQUNK-UHFFFAOYSA-N 0.000 claims description 3
- BLFNAQGIRJIUTL-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(4-butan-2-ylphenyl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=CC(C(C)CC)=CC=C1C1=CC(CN2C=C(N=C2)C(CC=2C=NC(N)=CC=2)C(O)=O)=NO1 BLFNAQGIRJIUTL-UHFFFAOYSA-N 0.000 claims description 3
- ZHTNBODNAJHAKP-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(4-fluorophenyl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C=2C=CC(F)=CC=2)=C1 ZHTNBODNAJHAKP-UHFFFAOYSA-N 0.000 claims description 3
- QWZUQMONGXLTQV-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(4-methylphenyl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=CC(C)=CC=C1C1=CC(CN2C=C(N=C2)C(CC=2C=NC(N)=CC=2)C(O)=O)=NO1 QWZUQMONGXLTQV-UHFFFAOYSA-N 0.000 claims description 3
- HKPURFXCABALOT-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C=2SC(Cl)=CC=2)=C1 HKPURFXCABALOT-UHFFFAOYSA-N 0.000 claims description 3
- LCBXXWMEIJJAOI-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-[4-(2-methylpropyl)phenyl]-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=CC(CC(C)C)=CC=C1C1=CC(CN2C=C(N=C2)C(CC=2C=NC(N)=CC=2)C(O)=O)=NO1 LCBXXWMEIJJAOI-UHFFFAOYSA-N 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 claims description 3
- 230000007211 cardiovascular event Effects 0.000 claims description 3
- 238000001212 derivatisation Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 3
- 201000005665 thrombophilia Diseases 0.000 claims description 3
- HKPURFXCABALOT-ZDUSSCGKSA-N (2s)-3-(6-aminopyridin-3-yl)-2-[1-[[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1C[C@H](C(O)=O)C(N=C1)=CN1CC1=NOC(C=2SC(Cl)=CC=2)=C1 HKPURFXCABALOT-ZDUSSCGKSA-N 0.000 claims description 2
- GPDUGVOFBWFPJM-UHFFFAOYSA-N 3-(6-amino-5-methylpyridin-3-yl)-2-[1-[(5-cyclopropyl-1,3,4-thiadiazol-2-yl)methyl]imidazol-4-yl]propanoic acid Chemical compound N1=C(N)C(C)=CC(CC(C(O)=O)C=2N=CN(CC=3SC(=NN=3)C3CC3)C=2)=C1 GPDUGVOFBWFPJM-UHFFFAOYSA-N 0.000 claims description 2
- LJOQOHFLKRBWLX-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[(5-cyclohexyl-1,2-oxazol-3-yl)methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C2CCCCC2)=C1 LJOQOHFLKRBWLX-UHFFFAOYSA-N 0.000 claims description 2
- WGPAYPGNQWEVGZ-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[(5-cyclohexyl-1,3,4-thiadiazol-2-yl)methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NN=C(C2CCCCC2)S1 WGPAYPGNQWEVGZ-UHFFFAOYSA-N 0.000 claims description 2
- FALBXQNLRHETDZ-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(2-chlorophenyl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C=2C(=CC=CC=2)Cl)=C1 FALBXQNLRHETDZ-UHFFFAOYSA-N 0.000 claims description 2
- ZKGJPEMZDXKWFR-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(4-cyclohexylphenyl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C=2C=CC(=CC=2)C2CCCCC2)=C1 ZKGJPEMZDXKWFR-UHFFFAOYSA-N 0.000 claims description 2
- AHHNSQCMCDOMKL-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(4-methoxyphenyl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=CC(OC)=CC=C1C1=CC(CN2C=C(N=C2)C(CC=2C=NC(N)=CC=2)C(O)=O)=NO1 AHHNSQCMCDOMKL-UHFFFAOYSA-N 0.000 claims description 2
- ROQSFKPHGVMRIX-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(4-propan-2-ylphenyl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=CC(C(C)C)=CC=C1C1=CC(CN2C=C(N=C2)C(CC=2C=NC(N)=CC=2)C(O)=O)=NO1 ROQSFKPHGVMRIX-UHFFFAOYSA-N 0.000 claims description 2
- LXVHQXHBJWZWOP-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(4-tert-butylphenyl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC(CN2C=C(N=C2)C(CC=2C=NC(N)=CC=2)C(O)=O)=NO1 LXVHQXHBJWZWOP-UHFFFAOYSA-N 0.000 claims description 2
- RIUBBCPPYHLKKY-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-[4-(2-phenylethyl)phenyl]-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C=2C=CC(CCC=3C=CC=CC=3)=CC=2)=C1 RIUBBCPPYHLKKY-UHFFFAOYSA-N 0.000 claims description 2
- MNOULQLXILYKNV-UHFFFAOYSA-N 5-[4-(trifluoromethyl)phenyl]-1h-pyrazole Chemical group C1=CC(C(F)(F)F)=CC=C1C1=CC=NN1 MNOULQLXILYKNV-UHFFFAOYSA-N 0.000 claims description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010047249 Venous thrombosis Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 238000002399 angioplasty Methods 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 2
- 230000003073 embolic effect Effects 0.000 claims description 2
- IJGGALRKWNQVQB-HNNXBMFYSA-N ethyl (2s)-3-(6-aminopyridin-3-yl)-2-[1-[[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoate Chemical compound C([C@H](C(=O)OCC)C=1N=CN(CC2=NOC(=C2)C=2SC(Cl)=CC=2)C=1)C1=CC=C(N)N=C1 IJGGALRKWNQVQB-HNNXBMFYSA-N 0.000 claims description 2
- 238000002513 implantation Methods 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 230000000250 revascularization Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- KVOZMFOBFOLFLZ-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(3,4-dichlorophenyl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C=2C=C(Cl)C(Cl)=CC=2)=C1 KVOZMFOBFOLFLZ-UHFFFAOYSA-N 0.000 claims 1
- PMHBMMFQGLYYPU-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(4-bromophenyl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C=2C=CC(Br)=CC=2)=C1 PMHBMMFQGLYYPU-UHFFFAOYSA-N 0.000 claims 1
- PNSLFOKYEVQVMK-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(4-butylphenyl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=CC(CCCC)=CC=C1C1=CC(CN2C=C(N=C2)C(CC=2C=NC(N)=CC=2)C(O)=O)=NO1 PNSLFOKYEVQVMK-UHFFFAOYSA-N 0.000 claims 1
- GCJYYHXIVLCDLD-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(5,6,7,8-tetrahydronaphthalen-2-yl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C=2C=C3CCCCC3=CC=2)=C1 GCJYYHXIVLCDLD-UHFFFAOYSA-N 0.000 claims 1
- 241000766026 Coregonus nasus Species 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 210000003127 knee Anatomy 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 71
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 70
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
- 235000019260 propionic acid Nutrition 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 238000005160 1H NMR spectroscopy Methods 0.000 description 26
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 15
- 125000001309 chloro group Chemical group Cl* 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 108090000201 Carboxypeptidase B2 Proteins 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 239000012312 sodium hydride Substances 0.000 description 8
- 229910000104 sodium hydride Inorganic materials 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- 102000003847 Carboxypeptidase B2 Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 102000010911 Enzyme Precursors Human genes 0.000 description 3
- 108010062466 Enzyme Precursors Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- QQIRAVWVGBTHMJ-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;lithium Chemical compound [Li].C[Si](C)(C)N[Si](C)(C)C QQIRAVWVGBTHMJ-UHFFFAOYSA-N 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 238000004296 chiral HPLC Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000020764 fibrinolysis Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 239000003880 polar aprotic solvent Substances 0.000 description 3
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- HKPURFXCABALOT-CYBMUJFWSA-N (2r)-3-(6-aminopyridin-3-yl)-2-[1-[[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1C[C@@H](C(O)=O)C(N=C1)=CN1CC1=NOC(C=2SC(Cl)=CC=2)=C1 HKPURFXCABALOT-CYBMUJFWSA-N 0.000 description 2
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- DNOFPUGBKLMYBA-UHFFFAOYSA-N 2-(bromomethyl)-6-chlorothieno[2,3-b]pyridine Chemical compound ClC1=CC=C2C=C(CBr)SC2=N1 DNOFPUGBKLMYBA-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- BYJWOQJVWRUSFB-UHFFFAOYSA-N 3-(4-aminocyclohexyl)-2-[1-[(5-cyclopropyl-1,3,4-thiadiazol-2-yl)methyl]imidazol-4-yl]propanoic acid Chemical compound C1CC(N)CCC1CC(C(O)=O)C(N=C1)=CN1CC1=NN=C(C2CC2)S1 BYJWOQJVWRUSFB-UHFFFAOYSA-N 0.000 description 2
- JRZVWHJISNBLPC-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[(5-cyclopentyl-1,3,4-thiadiazol-2-yl)methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NN=C(C2CCCC2)S1 JRZVWHJISNBLPC-UHFFFAOYSA-N 0.000 description 2
- VQSYFXGKPXAZDE-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[(5-cyclopropyl-1,3,4-thiadiazol-2-yl)methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NN=C(C2CC2)S1 VQSYFXGKPXAZDE-UHFFFAOYSA-N 0.000 description 2
- PYJFDCFRJHWHCG-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[(5-thiophen-2-yl-1,2-oxazol-3-yl)methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C=2SC=CC=2)=C1 PYJFDCFRJHWHCG-UHFFFAOYSA-N 0.000 description 2
- QJCNZXFWTRTHFG-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(4-cyclopentylphenyl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=NOC(C=2C=CC(=CC=2)C2CCCC2)=C1 QJCNZXFWTRTHFG-UHFFFAOYSA-N 0.000 description 2
- XTZFIZIBNICGRE-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(4-tert-butyl-2,6-dimethylphenyl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1C1=CC(CN2C=C(N=C2)C(CC=2C=NC(N)=CC=2)C(O)=O)=NO1 XTZFIZIBNICGRE-UHFFFAOYSA-N 0.000 description 2
- JXCVCCWUISUJCZ-UHFFFAOYSA-N 6-amino-2-[1-[(5-cyclopropyl-1,3,4-thiadiazol-2-yl)methyl]imidazol-4-yl]hexanoic acid Chemical compound C1=NC(C(C(O)=O)CCCCN)=CN1CC1=NN=C(C2CC2)S1 JXCVCCWUISUJCZ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N anhydrous trimethylamine Natural products CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000011260 aqueous acid Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- BGXVHTUUXRYWSM-UHFFFAOYSA-N diethyl 2-(1h-imidazol-5-yl)-2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]butyl]propanedioate Chemical compound CC(C)(C)OC(=O)NCCCCC(C(=O)OCC)(C(=O)OCC)C1=CNC=N1 BGXVHTUUXRYWSM-UHFFFAOYSA-N 0.000 description 2
- KNICDHZIBNZOCX-UHFFFAOYSA-N diethyl 2-[1-(4-methylphenyl)sulfonylimidazol-4-yl]-2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]butyl]propanedioate Chemical compound C1=NC(C(CCCCNC(=O)OC(C)(C)C)(C(=O)OCC)C(=O)OCC)=CN1S(=O)(=O)C1=CC=C(C)C=C1 KNICDHZIBNZOCX-UHFFFAOYSA-N 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 238000012153 long-term therapy Methods 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BAPKHGWQLQDOJK-UHFFFAOYSA-N methyl 3-(6-aminopyridin-3-yl)-2-(1h-imidazol-5-yl)propanoate Chemical compound C=1NC=NC=1C(C(=O)OC)CC1=CC=C(N)N=C1 BAPKHGWQLQDOJK-UHFFFAOYSA-N 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000019 pro-fibrinolytic effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000009863 secondary prevention Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- RZZURPLFMAFQCP-UHFFFAOYSA-N (4-bromothiophen-2-yl)methyl methanesulfonate Chemical compound CS(=O)(=O)OCC1=CC(Br)=CS1 RZZURPLFMAFQCP-UHFFFAOYSA-N 0.000 description 1
- NDVMIKMZXIGHMR-UHFFFAOYSA-N (5-cyclobutyl-1,2-oxazol-3-yl)methyl methanesulfonate Chemical compound O1N=C(COS(=O)(=O)C)C=C1C1CCC1 NDVMIKMZXIGHMR-UHFFFAOYSA-N 0.000 description 1
- JKVJMAIHGBOPRK-UHFFFAOYSA-N (5-cyclobutyl-1,3,4-thiadiazol-2-yl)methyl methanesulfonate Chemical compound S1C(COS(=O)(=O)C)=NN=C1C1CCC1 JKVJMAIHGBOPRK-UHFFFAOYSA-N 0.000 description 1
- MYBBNGNBKPKVKL-UHFFFAOYSA-N (5-cyclohexyl-1,2-oxazol-3-yl)methyl methanesulfonate Chemical compound O1N=C(COS(=O)(=O)C)C=C1C1CCCCC1 MYBBNGNBKPKVKL-UHFFFAOYSA-N 0.000 description 1
- DMXDJRAJRWGWFP-UHFFFAOYSA-N (5-cyclohexyl-1,3,4-thiadiazol-2-yl)methyl methanesulfonate Chemical compound S1C(COS(=O)(=O)C)=NN=C1C1CCCCC1 DMXDJRAJRWGWFP-UHFFFAOYSA-N 0.000 description 1
- JRAYABPWDBCPOO-UHFFFAOYSA-N (5-cyclopentyl-1,3,4-thiadiazol-2-yl)methyl methanesulfonate Chemical compound S1C(COS(=O)(=O)C)=NN=C1C1CCCC1 JRAYABPWDBCPOO-UHFFFAOYSA-N 0.000 description 1
- MCSWJILVUATFPB-UHFFFAOYSA-N (5-cyclopropyl-1,2-oxazol-3-yl)methyl methanesulfonate Chemical compound O1N=C(COS(=O)(=O)C)C=C1C1CC1 MCSWJILVUATFPB-UHFFFAOYSA-N 0.000 description 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229930182840 (S)-nicotine Natural products 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- DPZHKLJPVMYFCU-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)acetonitrile Chemical compound BrC1=CC=C(CC#N)N=C1 DPZHKLJPVMYFCU-UHFFFAOYSA-N 0.000 description 1
- AQQUODUHNQWXSO-UHFFFAOYSA-N 2-(bromomethyl)-5-(4-methoxyphenyl)-1,3,4-thiadiazole Chemical compound C1=CC(OC)=CC=C1C1=NN=C(CBr)S1 AQQUODUHNQWXSO-UHFFFAOYSA-N 0.000 description 1
- ITNVXASBWCQERP-UHFFFAOYSA-N 2-(bromomethyl)-5-(5-chlorothiophen-2-yl)-1,3,4-thiadiazole Chemical compound S1C(Cl)=CC=C1C1=NN=C(CBr)S1 ITNVXASBWCQERP-UHFFFAOYSA-N 0.000 description 1
- QJHYCCBKRALUJV-UHFFFAOYSA-N 2-(chloromethyl)-5-(4-chlorophenyl)-1,3,4-thiadiazole Chemical compound S1C(CCl)=NN=C1C1=CC=C(Cl)C=C1 QJHYCCBKRALUJV-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UBRVEHYDNDGKSN-UHFFFAOYSA-N 2-[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCC1=NOC(C=2SC(Cl)=CC=2)=C1 UBRVEHYDNDGKSN-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- ZLQQUIHBQATFOP-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-5-(chloromethyl)-1,2,4-oxadiazole Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=NOC(CCl)=N1 ZLQQUIHBQATFOP-UHFFFAOYSA-N 0.000 description 1
- IFHWJTOFROTZBD-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-(1h-imidazol-5-yl)propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C1=CNC=N1 IFHWJTOFROTZBD-UHFFFAOYSA-N 0.000 description 1
- HUFICPNMQKBWFK-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[(4-bromothiophen-2-yl)methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=CC(Br)=CS1 HUFICPNMQKBWFK-UHFFFAOYSA-N 0.000 description 1
- DSTAIOCBKUINOO-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[(5-methyl-1,2-oxazol-3-yl)methyl]imidazol-4-yl]propanoic acid Chemical compound O1C(C)=CC(CN2C=C(N=C2)C(CC=2C=NC(N)=CC=2)C(O)=O)=N1 DSTAIOCBKUINOO-UHFFFAOYSA-N 0.000 description 1
- LTGZLPZWHMBCQQ-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[(5-tert-butyl-1,3,4-thiadiazol-2-yl)methyl]imidazol-4-yl]propanoic acid Chemical compound S1C(C(C)(C)C)=NN=C1CN1C=C(C(CC=2C=NC(N)=CC=2)C(O)=O)N=C1 LTGZLPZWHMBCQQ-UHFFFAOYSA-N 0.000 description 1
- MYVMXNFSPZGCOB-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[(6-chlorothieno[2,3-b]pyridin-2-yl)methyl]imidazol-4-yl]propanoic acid Chemical compound C1=NC(N)=CC=C1CC(C(O)=O)C(N=C1)=CN1CC1=CC2=CC=C(Cl)N=C2S1 MYVMXNFSPZGCOB-UHFFFAOYSA-N 0.000 description 1
- LYKUWXWTDOODSN-UHFFFAOYSA-N 3-(6-aminopyridin-3-yl)-2-[1-[[5-(4-propylphenyl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoic acid Chemical compound C1=CC(CCC)=CC=C1C1=CC(CN2C=C(N=C2)C(CC=2C=NC(N)=CC=2)C(O)=O)=NO1 LYKUWXWTDOODSN-UHFFFAOYSA-N 0.000 description 1
- WNDBXQJUQYWZGG-UHFFFAOYSA-N 3-(bromomethyl)-5-(2-methyl-1,3-thiazol-4-yl)-1,2-oxazole Chemical compound S1C(C)=NC(C=2ON=C(CBr)C=2)=C1 WNDBXQJUQYWZGG-UHFFFAOYSA-N 0.000 description 1
- RQINPRKPXYMLDP-UHFFFAOYSA-N 3-(bromomethyl)-5-(3,4-dichlorophenyl)-1,2-oxazole Chemical compound C1=C(Cl)C(Cl)=CC=C1C1=CC(CBr)=NO1 RQINPRKPXYMLDP-UHFFFAOYSA-N 0.000 description 1
- KTMPYEMADWFWEF-UHFFFAOYSA-N 3-(bromomethyl)-5-(3-methylbutyl)-1,2-oxazole Chemical compound CC(C)CCC1=CC(CBr)=NO1 KTMPYEMADWFWEF-UHFFFAOYSA-N 0.000 description 1
- YMIYHZCXVALGGW-UHFFFAOYSA-N 3-(bromomethyl)-5-(4-methoxyphenyl)-1,2-oxazole Chemical compound C1=CC(OC)=CC=C1C1=CC(CBr)=NO1 YMIYHZCXVALGGW-UHFFFAOYSA-N 0.000 description 1
- UBIXPIXAVFHKMM-UHFFFAOYSA-N 3-(bromomethyl)-5-(5-chlorothiophen-2-yl)-1,2-oxazole Chemical compound S1C(Cl)=CC=C1C1=CC(CBr)=NO1 UBIXPIXAVFHKMM-UHFFFAOYSA-N 0.000 description 1
- ASGJFGPILHALRC-UHFFFAOYSA-N 3-(bromomethyl)-5-methyl-1,2-oxazole Chemical compound CC1=CC(CBr)=NO1 ASGJFGPILHALRC-UHFFFAOYSA-N 0.000 description 1
- NEBKJFRUXVPDFH-UHFFFAOYSA-N 3-(bromomethyl)-5-phenyl-1,2-oxazole Chemical compound O1N=C(CBr)C=C1C1=CC=CC=C1 NEBKJFRUXVPDFH-UHFFFAOYSA-N 0.000 description 1
- LSYCZBSPYWGGHC-UHFFFAOYSA-N 3-(chloromethyl)-5-(4-methoxyphenyl)-1,2,4-oxadiazole Chemical compound C1=CC(OC)=CC=C1C1=NC(CCl)=NO1 LSYCZBSPYWGGHC-UHFFFAOYSA-N 0.000 description 1
- INANILNLXTUPHD-UHFFFAOYSA-N 3-(chloromethyl)-5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2ON=C(CCl)N=2)=C1 INANILNLXTUPHD-UHFFFAOYSA-N 0.000 description 1
- IOVWIIJODVBCRC-UHFFFAOYSA-N 3-(chloromethyl)-5-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=NC(CCl)=NO1 IOVWIIJODVBCRC-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- HBGBCVMONHPTMC-UHFFFAOYSA-N 5-(bromomethyl)-2-(5-chlorothiophen-2-yl)-1,3-thiazole Chemical compound S1C(Cl)=CC=C1C1=NC=C(CBr)S1 HBGBCVMONHPTMC-UHFFFAOYSA-N 0.000 description 1
- PROALHWGUKNCJY-UHFFFAOYSA-N 5-(chloromethyl)-3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazole Chemical compound C1=C(OC)C(OC)=CC=C1C1=NOC(CCl)=N1 PROALHWGUKNCJY-UHFFFAOYSA-N 0.000 description 1
- DNEALSFRYSYSDL-UHFFFAOYSA-N 5-(chloromethyl)-3-(4-methoxyphenyl)-1,2,4-oxadiazole Chemical compound C1=CC(OC)=CC=C1C1=NOC(CCl)=N1 DNEALSFRYSYSDL-UHFFFAOYSA-N 0.000 description 1
- DJXRLUNPDLKRQB-UHFFFAOYSA-N 5-(chloromethyl)-3-(4-propan-2-ylphenyl)-1,2,4-oxadiazole Chemical compound C1=CC(C(C)C)=CC=C1C1=NOC(CCl)=N1 DJXRLUNPDLKRQB-UHFFFAOYSA-N 0.000 description 1
- JQXINYPZWYBYKO-UHFFFAOYSA-N 5-(chloromethyl)-3-[4-[(4-chlorophenyl)methoxy]phenyl]-1,2,4-oxadiazole Chemical compound O1C(CCl)=NC(C=2C=CC(OCC=3C=CC(Cl)=CC=3)=CC=2)=N1 JQXINYPZWYBYKO-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- DNMFLQPOZVDJNI-UHFFFAOYSA-N 5-methylidene-4h-pyridin-2-amine Chemical compound NC1=CCC(=C)C=N1 DNMFLQPOZVDJNI-UHFFFAOYSA-N 0.000 description 1
- AIVSLDAXUIRICJ-UHFFFAOYSA-N 5-tert-butyl-3-(chloromethyl)-1,2,4-oxadiazole Chemical compound CC(C)(C)C1=NC(CCl)=NO1 AIVSLDAXUIRICJ-UHFFFAOYSA-N 0.000 description 1
- FUTYTLQGHKTOLU-UHFFFAOYSA-N 6-chlorothieno[2,3-b]pyridine-2-carbaldehyde Chemical compound ClC1=CC=C2C=C(C=O)SC2=N1 FUTYTLQGHKTOLU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- 102000003670 Carboxypeptidase B Human genes 0.000 description 1
- 108090000087 Carboxypeptidase B Proteins 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 229930028154 D-arginine Natural products 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 102000012607 Thrombomodulin Human genes 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- LUGYXRSNCSITRC-UHFFFAOYSA-N [4-phenyl-5-(trifluoromethyl)thiophen-2-yl]methyl methanesulfonate Chemical compound S1C(COS(=O)(=O)C)=CC(C=2C=CC=CC=2)=C1C(F)(F)F LUGYXRSNCSITRC-UHFFFAOYSA-N 0.000 description 1
- AVUDKHPQZWWTEE-UHFFFAOYSA-N [5-(2,3-dihydro-1,4-benzodioxin-6-yl)-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound O1N=C(COS(=O)(=O)C)C=C1C1=CC=C(OCCO2)C2=C1 AVUDKHPQZWWTEE-UHFFFAOYSA-N 0.000 description 1
- RZYBTIAJHJGGDR-UHFFFAOYSA-N [5-(2,3-dihydro-1h-inden-5-yl)-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound O1N=C(COS(=O)(=O)C)C=C1C1=CC=C(CCC2)C2=C1 RZYBTIAJHJGGDR-UHFFFAOYSA-N 0.000 description 1
- GLRRKWWOZRCBGI-UHFFFAOYSA-N [5-(2-chlorophenyl)-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound O1N=C(COS(=O)(=O)C)C=C1C1=CC=CC=C1Cl GLRRKWWOZRCBGI-UHFFFAOYSA-N 0.000 description 1
- PZUCPXKRDZLGSI-UHFFFAOYSA-N [5-(4-benzylphenyl)-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound O1N=C(COS(=O)(=O)C)C=C1C(C=C1)=CC=C1CC1=CC=CC=C1 PZUCPXKRDZLGSI-UHFFFAOYSA-N 0.000 description 1
- MQPQEGUOBZIHTL-UHFFFAOYSA-N [5-(4-bromophenyl)-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound O1N=C(COS(=O)(=O)C)C=C1C1=CC=C(Br)C=C1 MQPQEGUOBZIHTL-UHFFFAOYSA-N 0.000 description 1
- MUVRLCMMOVUVNR-UHFFFAOYSA-N [5-(4-butan-2-ylphenyl)-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound C1=CC(C(C)CC)=CC=C1C1=CC(COS(C)(=O)=O)=NO1 MUVRLCMMOVUVNR-UHFFFAOYSA-N 0.000 description 1
- ZBHDQDNFQRBMTA-UHFFFAOYSA-N [5-(4-butylphenyl)-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound C1=CC(CCCC)=CC=C1C1=CC(COS(C)(=O)=O)=NO1 ZBHDQDNFQRBMTA-UHFFFAOYSA-N 0.000 description 1
- QZKAXFCSOAQPJF-UHFFFAOYSA-N [5-(4-cyclohexylphenyl)-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound O1N=C(COS(=O)(=O)C)C=C1C1=CC=C(C2CCCCC2)C=C1 QZKAXFCSOAQPJF-UHFFFAOYSA-N 0.000 description 1
- YPAMMMTXDJPJHS-UHFFFAOYSA-N [5-(4-cyclopentylphenyl)-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound O1N=C(COS(=O)(=O)C)C=C1C1=CC=C(C2CCCC2)C=C1 YPAMMMTXDJPJHS-UHFFFAOYSA-N 0.000 description 1
- GQDZTNBBKGYJAT-UHFFFAOYSA-N [5-(4-fluorophenyl)-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound O1N=C(COS(=O)(=O)C)C=C1C1=CC=C(F)C=C1 GQDZTNBBKGYJAT-UHFFFAOYSA-N 0.000 description 1
- OIYLLLDGJNTDOR-UHFFFAOYSA-N [5-(4-methylphenyl)-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound C1=CC(C)=CC=C1C1=CC(COS(C)(=O)=O)=NO1 OIYLLLDGJNTDOR-UHFFFAOYSA-N 0.000 description 1
- QTAHZEZXRXCBCG-UHFFFAOYSA-N [5-(4-propan-2-ylphenyl)-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound C1=CC(C(C)C)=CC=C1C1=CC(COS(C)(=O)=O)=NO1 QTAHZEZXRXCBCG-UHFFFAOYSA-N 0.000 description 1
- ITZYRHCXCQACKQ-UHFFFAOYSA-N [5-(4-propylphenyl)-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound C1=CC(CCC)=CC=C1C1=CC(COS(C)(=O)=O)=NO1 ITZYRHCXCQACKQ-UHFFFAOYSA-N 0.000 description 1
- ZMAWGPSYYNCCDJ-UHFFFAOYSA-N [5-(4-tert-butyl-2,6-dimethylphenyl)-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1C1=CC(COS(C)(=O)=O)=NO1 ZMAWGPSYYNCCDJ-UHFFFAOYSA-N 0.000 description 1
- JWKKOQCQEJHPFV-UHFFFAOYSA-N [5-(4-tert-butylphenyl)-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC(COS(C)(=O)=O)=NO1 JWKKOQCQEJHPFV-UHFFFAOYSA-N 0.000 description 1
- LICZKAOIJVOZCY-UHFFFAOYSA-N [5-(5,6,7,8-tetrahydronaphthalen-2-yl)-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound O1N=C(COS(=O)(=O)C)C=C1C1=CC=C(CCCC2)C2=C1 LICZKAOIJVOZCY-UHFFFAOYSA-N 0.000 description 1
- WKFXNWVTIMYEBF-UHFFFAOYSA-N [5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound O1N=C(COS(=O)(=O)C)C=C1C1=CC=C(Cl)S1 WKFXNWVTIMYEBF-UHFFFAOYSA-N 0.000 description 1
- CVXCNVAPMWBFMB-UHFFFAOYSA-N [5-[4-(2-methylpropyl)phenyl]-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound C1=CC(CC(C)C)=CC=C1C1=CC(COS(C)(=O)=O)=NO1 CVXCNVAPMWBFMB-UHFFFAOYSA-N 0.000 description 1
- OWZYBQQHMYNEPI-UHFFFAOYSA-N [5-[4-(2-phenylethyl)phenyl]-1,2-oxazol-3-yl]methyl methanesulfonate Chemical compound O1N=C(COS(=O)(=O)C)C=C1C(C=C1)=CC=C1CCC1=CC=CC=C1 OWZYBQQHMYNEPI-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- BAIKZTRFGPDIIT-UHFFFAOYSA-N diethyl 2-[1-(4-methylphenyl)sulfonylimidazol-4-yl]propanedioate Chemical compound C1=NC(C(C(=O)OCC)C(=O)OCC)=CN1S(=O)(=O)C1=CC=C(C)C=C1 BAIKZTRFGPDIIT-UHFFFAOYSA-N 0.000 description 1
- BGTSPNSMDHBKFX-UHFFFAOYSA-N diethyl 2-[1-[(5-cyclopropyl-1,3,4-thiadiazol-2-yl)methyl]imidazol-4-yl]-2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]butyl]propanedioate Chemical compound C1=NC(C(CCCCNC(=O)OC(C)(C)C)(C(=O)OCC)C(=O)OCC)=CN1CC1=NN=C(C2CC2)S1 BGTSPNSMDHBKFX-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- IJGGALRKWNQVQB-OAHLLOKOSA-N ethyl (2r)-3-(6-aminopyridin-3-yl)-2-[1-[[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoate Chemical compound C([C@@H](C(=O)OCC)C=1N=CN(CC2=NOC(=C2)C=2SC(Cl)=CC=2)C=1)C1=CC=C(N)N=C1 IJGGALRKWNQVQB-OAHLLOKOSA-N 0.000 description 1
- DHVLEUPHIBFAJP-UHFFFAOYSA-N ethyl 2-[1-(4-methylphenyl)sulfonylimidazol-4-yl]acetate Chemical compound C1=NC(CC(=O)OCC)=CN1S(=O)(=O)C1=CC=C(C)C=C1 DHVLEUPHIBFAJP-UHFFFAOYSA-N 0.000 description 1
- MSMGXWFHBSCQFB-UHFFFAOYSA-N ethyl cyanoformate Chemical compound CCOC(=O)C#N MSMGXWFHBSCQFB-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000208 fibrin degradation product Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229940049370 fibrinolysis inhibitor Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 150000002669 lysines Chemical group 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- BGPQBVSYPNMCPL-UHFFFAOYSA-N methyl 3-(6-aminopyridin-3-yl)-2-[1-[(5-phenyl-1,2-oxazol-3-yl)methyl]imidazol-4-yl]propanoate Chemical compound C=1N(CC2=NOC(=C2)C=2C=CC=CC=2)C=NC=1C(C(=O)OC)CC1=CC=C(N)N=C1 BGPQBVSYPNMCPL-UHFFFAOYSA-N 0.000 description 1
- COUHXNZKIWFVIY-UHFFFAOYSA-N methyl 3-(6-aminopyridin-3-yl)-2-[1-[[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]methyl]imidazol-4-yl]propanoate Chemical compound C=1N(CC2=NOC(=C2)C=2SC(Cl)=CC=2)C=NC=1C(C(=O)OC)CC1=CC=C(N)N=C1 COUHXNZKIWFVIY-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000018341 negative regulation of fibrinolysis Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- GKGFAEREWWZBKY-UHFFFAOYSA-N tert-butyl n-(4-bromobutyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCBr GKGFAEREWWZBKY-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005049385A DE102005049385A1 (de) | 2005-10-15 | 2005-10-15 | Imidazolderivate als Inhibitoren von TAFIa |
| PCT/EP2006/009500 WO2007045339A1 (de) | 2005-10-15 | 2006-09-30 | Imidazolderivate als inhibitoren von tafi-a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1937673T3 true DK1937673T3 (en) | 2016-01-25 |
Family
ID=37733974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06792327.6T DK1937673T3 (en) | 2005-10-15 | 2006-09-30 | Imidazolderivater som hæmmere af tafi-a |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8044208B2 (https=) |
| EP (1) | EP1937673B1 (https=) |
| JP (1) | JP5266053B2 (https=) |
| CY (1) | CY1117379T1 (https=) |
| DE (1) | DE102005049385A1 (https=) |
| DK (1) | DK1937673T3 (https=) |
| ES (1) | ES2558874T3 (https=) |
| HU (1) | HUE026577T2 (https=) |
| PL (1) | PL1937673T3 (https=) |
| PT (1) | PT1937673E (https=) |
| SI (1) | SI1937673T1 (https=) |
| WO (1) | WO2007045339A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009103432A2 (en) * | 2008-02-21 | 2009-08-27 | Sanofi-Aventis | Covalently binding imaging probes |
| NZ592764A (en) * | 2008-10-29 | 2012-08-31 | Taisho Pharmaceutical Co Ltd | Compound having tafia inhibitory activity |
| DK2548871T3 (da) | 2010-03-18 | 2017-11-06 | Daiichi Sankyo Co Ltd | Cycloalkylsubstitueret imidazolderivat |
| KR20130006620A (ko) * | 2010-03-18 | 2013-01-17 | 다이이찌 산쿄 가부시키가이샤 | 시클로프로판카르복실산 유도체 |
| KR101799429B1 (ko) | 2010-05-03 | 2017-11-21 | 에스케이바이오팜 주식회사 | 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물 |
| US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
| US8809372B2 (en) | 2011-09-30 | 2014-08-19 | Asana Biosciences, Llc | Pyridine derivatives |
| CA2914533A1 (en) | 2013-06-10 | 2014-12-18 | Sanofi | Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals |
| AU2020407664A1 (en) | 2019-12-20 | 2022-08-18 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| AU2022270657A1 (en) | 2021-05-04 | 2023-11-16 | Tenaya Therapeutics, Inc. | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL361054A1 (en) * | 2000-08-17 | 2004-09-20 | Pfizer Inc. | Substituted imidazoles as tafia inhibitors |
| WO2003013526A1 (en) * | 2001-08-08 | 2003-02-20 | Merck & Co. Inc. | Anticoagulant compounds |
| WO2003061653A1 (en) * | 2002-01-22 | 2003-07-31 | Pfizer Limited | 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
-
2005
- 2005-10-15 DE DE102005049385A patent/DE102005049385A1/de not_active Withdrawn
-
2006
- 2006-09-30 EP EP06792327.6A patent/EP1937673B1/de not_active Not-in-force
- 2006-09-30 HU HUE06792327A patent/HUE026577T2/hu unknown
- 2006-09-30 ES ES06792327.6T patent/ES2558874T3/es active Active
- 2006-09-30 PT PT67923276T patent/PT1937673E/pt unknown
- 2006-09-30 WO PCT/EP2006/009500 patent/WO2007045339A1/de not_active Ceased
- 2006-09-30 JP JP2008534894A patent/JP5266053B2/ja not_active Expired - Fee Related
- 2006-09-30 SI SI200632014T patent/SI1937673T1/sl unknown
- 2006-09-30 PL PL06792327T patent/PL1937673T3/pl unknown
- 2006-09-30 DK DK06792327.6T patent/DK1937673T3/en active
-
2008
- 2008-04-14 US US12/102,105 patent/US8044208B2/en not_active Expired - Fee Related
-
2016
- 2016-01-20 CY CY20161100053T patent/CY1117379T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1117379T1 (el) | 2017-04-26 |
| HUE026577T2 (hu) | 2016-06-28 |
| WO2007045339A1 (de) | 2007-04-26 |
| SI1937673T1 (sl) | 2016-02-29 |
| EP1937673B1 (de) | 2015-10-21 |
| US8044208B2 (en) | 2011-10-25 |
| ES2558874T3 (es) | 2016-02-09 |
| JP2009511516A (ja) | 2009-03-19 |
| DE102005049385A1 (de) | 2007-04-19 |
| EP1937673A1 (de) | 2008-07-02 |
| PL1937673T3 (pl) | 2016-03-31 |
| JP5266053B2 (ja) | 2013-08-21 |
| PT1937673E (pt) | 2016-02-08 |
| US20080262028A1 (en) | 2008-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8044208B2 (en) | Imidazole derivatives as inhibitors of TAFIa | |
| US9126955B2 (en) | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | |
| ES2299026T3 (es) | Derivados de imidazol en calidad de inhibidores de tafia. | |
| CA2623294C (en) | 2-aminoethoxyacetic acid derivatives and their use | |
| JP5249226B2 (ja) | 凝固第ＩＸａ因子インヒビターとしての使用のためのイソセリン誘導体 | |
| DK2104497T3 (en) | SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | |
| JP2010511034A (ja) | 第Ｘａ因子阻害剤としての（Ｒ）−５−メチル−４，５−ジヒドロ−ピラゾール−１，５−ジカルボン酸１−［（４−クロロ−フェニル）−アミド］５−｛［２−フルオロ−４−（２−オキソ−２Ｈ−ピリジン−１−イル）−フェニル］−アミド｝ | |
| CA2448639A1 (en) | Novel heterocyclic derivatives and medicinal use thereof | |
| TW200829557A (en) | Tartrate derivatives as inhibitors of coagulation factor IXa | |
| KR100854584B1 (ko) | 피리다지논, 피리미돈 또는 피리돈 구조를 포함하는선택적인 트롬빈 억제제 | |
| HK1064372A (en) | Novel heterocyclic derivatives and medicinal use thereof | |
| HK1152936B (en) | Macrocyclic urea derivatives and sulfamide derivatives as inhibitors of tafia |